| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
5-Fluorocytidine targets enzymes involved in nucleic acid metabolism. As a cytidine analog, it may be phosphorylated by cellular kinases to the corresponding nucleotide and incorporated into RNA, leading to disruption of RNA synthesis and function. The compound may also inhibit enzymes involved in pyrimidine metabolism.
|
|---|---|
| ln Vitro |
In vitro, 5-fluorocytidine may exhibit cytotoxic activity against cancer cell lines through incorporation into RNA and interference with RNA function. It may also demonstrate antiviral activity by inhibiting viral RNA synthesis. Specific activity data for this compound are limited in the published literature.
|
| ln Vivo |
In vivo activity data for 5-fluorocytidine are limited in the published literature. As a nucleoside analog, it would be expected to require metabolic activation through phosphorylation to exert its effects.
|
| Enzyme Assay |
In vitro enzyme assays for 5-fluorocytidine may involve kinases that phosphorylate the compound, or enzymes involved in pyrimidine metabolism.
|
| Cell Assay |
Cellular assays for 5-fluorocytidine are performed using cancer cell lines or virus-infected cells. Cells are treated with the compound at various concentrations for 24-72 hours, and cell viability or viral replication is assessed.
|
| Animal Protocol |
In vivo animal studies for 5-fluorocytidine are not extensively documented. As a nucleoside analog, potential applications would be in cancer or antiviral research.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for 5-fluorocytidine are limited. As a nucleoside, it would be expected to be phosphorylated intracellularly and incorporated into nucleic acids.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 5-fluorocytidine are limited. As a nucleoside analog, it may have cytotoxic effects.
|
| References | |
| Additional Infomation |
5-Fluorocytidine is an organofluorine compound belonging to the cytidine class of compounds.
5-Fluorocytidine is a fluorinated nucleoside analog with potential anticancer and antiviral applications. The compound is not approved for clinical use; all applications remain at the research stage. |
| Molecular Formula |
C9H12FN3O5
|
|---|---|
| Molecular Weight |
261.21
|
| Exact Mass |
261.076
|
| CAS # |
2341-22-2
|
| PubChem CID |
16861
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
511.4±60.0 °C at 760 mmHg
|
| Melting Point |
196-200 °C(lit.)
|
| Flash Point |
263.1±32.9 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.732
|
| LogP |
-1.67
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
426
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=C(C(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)F
|
| InChi Key |
STRZQWQNZQMHQR-UAKXSSHOSA-N
|
| InChi Code |
InChI=1S/C9H12FN3O5/c10-3-1-13(9(17)12-7(3)11)8-6(16)5(15)4(2-14)18-8/h1,4-6,8,14-16H,2H2,(H2,11,12,17)/t4-,5-,6-,8-/m1/s1
|
| Chemical Name |
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~382.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8283 mL | 19.1417 mL | 38.2834 mL | |
| 5 mM | 0.7657 mL | 3.8283 mL | 7.6567 mL | |
| 10 mM | 0.3828 mL | 1.9142 mL | 3.8283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
